Healthcare Industry News: human embryonic stem cell
News Release - July 29, 2008
ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
ATHENS, Ga., July 29 (HSMN NewsFeed) -- ArunA Biomedical, Inc., the first company to commercialize human embryonic stem cell derived products and services, announced today that William T. Sharp has been named President and Chief Executive Officer. In addition to his ArunA leadership responsibilities, Mr. Sharp has also been appointed to ArunA's Board of Directors. Mr. Sharp succeeds ArunA founder Steven Stice, PhD, who will remain ArunA's Chairman and Chief Scientific Officer. Dr. Stice remarked, "We are pleased to welcome Bill to ArunA. Bill has an extensive background leading life science businesses and his leadership is critical to the success of the company's next phase of growth. Bill's experience and expertise in the industry are key elements to further positioning ArunA as the industry leader in this emerging market."Mr. Sharp brings more that twenty-five years of industry leadership experience to ArunA Biomedical. His experience spans Fortune 500 to emerging and mid-sized businesses in the life science tools, diagnostics and clinical markets and Mr. Sharp has played major roles in mergers and acquisitions of several companies. Most recently, Mr. Sharp served as Chief Commercial Officer of BioProcessors Corporation, a venture-financed life science tools developer based in the Boston area, where he led global commercialization efforts of the company's proprietary high-throughput mammalian cell culture technology. Prior to BioProcessors, Mr. Sharp was Senior VP of Business Development with Cellomics (acquired by Fisher), Vice President of Business Development with Gentra Systems (now Qiagen), Worldwide Director for the Molecular Biology Business of Life Technologies (now Invitrogen), and Vice President of Sales and Marketing with Heraeus Instruments. Mr. Sharp holds MS and BA degrees from The Pennsylvania State University.
"Steve Stice and ArunA's outstanding team of scientists are dedicated to discovering and developing tools that will ultimately create opportunities to improve the quality of life for millions of people suffering from devastating diseases," stated Mr. Sharp. "ArunA's first commercial product, ENSTem-A(TM), is based on a proprietary technology licensed from the University of Georgia and is commercially available through a distribution relationship with Millipore Corporation. This product, along with several others in ArunA's near-term development pipeline, should help to accelerate the pace of research for scientists around the world. I am thrilled to be associated with a company on the leading edge of such a promising field. I look forward to leading ArunA as we proceed down a path of continuous and rapid development of enabling new products and services that will serve as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases."
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, ENSTem-A(TM), was introduced through a distribution relationship with Millipore in 2007 and is based on proprietary technology licensed from the University of Georgia. ArunA also provides comprehensive testing and assay services based on their expertise and unique human stem cell derived research tools. For more information, visit www.arunabiomedical.com.
Source: ArunA Biomedical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
